Corporate
News Releases
2019
November
Pharmaceuticals
POConePlus® Infrared Spectrophotometer for Diagnosis of H. pylori infection launched in Japan
Corporate
Construction Completed on Otsuka's New Pharmaceutical Factory Plant in Mima City, Tokushima Prefecture, Japan
Pharmaceuticals
Otsuka Launches New SAMSCA Formulation in Japan: SAMSCA® OD Tablets
Corporate
Otsuka Pharmaceutical Cosponsors "Asan Walking Festa in Itano" as Part of Community Health Promotion Efforts
Pharmaceuticals
Otsuka Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development ofInvestigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia
October
Pharmaceuticals
RS Virus Rapid-measurement Kit Quick NaviTM-RSV2 To Be Launched in Japan- Faster test results and enhanced visual features with two color lines -
Nutraceuticals
Presentation of Effects of lactic acid bacterium B240 at Palynological Society of Japan
Nutraceuticals
Three New Flavors of Easy-to-Drink Balanced Nutrition BeverageIntroducing Calorie Mate Liquid
September
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
Pharmaceuticals
Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension
Nutraceuticals
New Series Expands the SOYJOY Line of Whole Soy Nutrition Bars SOYJOY Scone Bar Plain
Corporate
Otsuka Pharmaceutical Greenhouse Gas Emissions Reduction Targets Earn Science Based Targets (SBT) Initiative Certification
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreement with Niigata Prefecture to Support Prefectural Residents' Health Promotion Project
August
Pharmaceuticals
Approval for the Additional Formulation of Samsca® OD Tablets in Japan
Nutraceuticals
UL·OS Men's Skincare BrandRenewal Launch of Three Moisturizing Products
Corporate
Otsuka Group Adopts CO2-free Electricity Annual CO2 Emissions to Decline by Approximately 9%
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink PRESENTS Awa Odori Sound Festival
June
Nutraceuticals
POCARI SWEAT Marketing Wins Top Prize at Japan Marketing Awards
Nutraceuticals
Deliciously Illustrated SketchCook Wins in Three Categories at PR Awards Asia 2019 ― Dietary education app promotes awareness about the importance of meals and nutrition to children―
Pharmaceuticals
Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
Pharmaceuticals
Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727
April
March
Nutraceuticals
Otsuka Pharmaceutical to Sponsor 30th Southeast Asian Games 2019 (Philippines)
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
Pharmaceuticals
Notice regarding the conclusion of co-development/co-promotion activities in Japan for the anti-epileptic drug "E Keppra"
Corporate
Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors (PDF: 56.8 KB)
Pharmaceuticals
Selincro Tablets 10mg Launched in Japan
February
Nutraceuticals
Refreshing Men's Facial Lotion for Summer ComfortIntroducing UL·OS Medicated Skin Breezy LotionA single product to moisturize, minimize oily shine, and prevent formation of blemishes
Nutraceuticals
Otsuka Pharmaceutical to Serve as an Official Partner for Tokyo Marathon 2019New "Run," "Support," "Boost," Program Benefits All Participants
Pharmaceuticals
Otsuka and Lundbeck report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
Pharmaceuticals
Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"
Pharmaceuticals
Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA (dextromethorphan HBr and quinidine sulfate) 20 mg/10 mg capsule
Pharmaceuticals
The 1st Japan Open Innovation Prize
Nutraceuticals